Health
Dartmouth TB vaccine moves one step closer to a full Phase 3 efficacy trial – News-Medical.Net
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth’s Geisel School of Medicine and publi…
Reviewed by Emily Henderson, B.Sc.Sep 29 2020
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induced immune responses against the disease.
Tuberculosis is most common infectious disease cause of death in…
-
Business21 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
General15 hours agoMan charged with murder after alleged assault victim dies in Hervey Bay
-
General16 hours agoGrieving Bunbury family outraged over plan to remove roadside memorial
-
Business15 hours agoAustralian rare earths companies trading at record levels as China tightens export controls